GW2580 (SC203877)

Alias: GW 2580; SC-203877; SC 203877; GW 2580; GW-2580; SC203877
Cat No.:V0633 Purity: ≥98%
GW2580 (also known as SC-203877)is a novel, potent, selective, and orally bioavailable c-Fms kinaseCSF-1R inhibitor with potential antineoplastic activity.
GW2580 (SC203877) Chemical Structure CAS No.: 870483-87-7
Product category: CSF-1R
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
1g
2g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Purity: ≥98%

Purity: ≥98%

Product Description

GW2580 (also known as SC-203877) is a novel, potent, selective, and orally bioavailable c-Fms kinase CSF-1R inhibitor with potential antineoplastic activity. It inhibits c-Fms kinase CSF-1R with an IC50 of 30 nM, and displays 150- to 500-fold selectivity for c-Fms kinase CSF-1R over other kinases such as b-Raf, GSK3, ITK, CDK4, c-KIT, ERBB2/4, ERK2, FLT-3, c-SRC, EGFR, JAK2 etc. It exhibits high in vivo antitumor efficacy in mouse bearing myeloid carcinoma xenografts M-NFS-60.

Biological Activity I Assay Protocols (From Reference)
Targets
c-FMS (IC50 = 60 nM)
ln Vitro
GW2580 completely inhibits human cFMS kinase in vitro at a concentration of 0.06 μM. With an IC50 of 0.33, 13.5, 0.47, and 12 μM, respectively, GW2580 suppresses the growth of myeloid tumor cells stimulated by CSF-1, serum-stimulated NSO myeloid tumor cells, freshly isolated human monocytes stimulated by CSF-1, and human umbilical vein vascular endothelial cells stimulated by VEGF. A single microm Complete inhibition of bone degradation in cultures of human osteoclasts, rat calvaria, and rat fetal long bone is observed with GW2580. It also completely inhibits the growth of mouse M-NFS-60 myeloid cells and human monocytes induced by CSF-1.[1] With an IC50 of about 10 nM, GW2580 suppresses CSF1R phosphorylation in RAW264.7 murine macrophages stimulated with 10 ng/mL. With an IC50 of 0.88 μM, GW2580 likewise suppresses TRKA activity [2][3]
ln Vivo
GW2580 (dosed orally at 40 mg/kg 0.5 h before the CSF-1-priming dose) suppresses the 63% increase in TNF-α production in mice induced by LPS when exogenous CSF-1 is added. GW2580 completely prevents CSF-1 from priming mice for enhanced IL-6 production when it is administered to them prior to CSF-1 priming. The peritoneal cavity's M-NFS-60 tumor cells that are dependent on CSF-1 are totally inhibited from growing by GW2580 (80 mg/kg p.o.). When taken orally twice a day the week prior to and for four days following thioglycolate injection, GW2580 (80 mg/kg) reduces (by 45%) the amount of macrophages that accumulate in the peritoneal cavity.[1] GW2580 (50 mg/kg), administered twice daily from days 0 to 21, 7 to 21, or 14 to 21, inhibits the breakdown of joint connective tissue and bone in a 21-day adjuvant arthritis model.[3] By preventing the tumor from recruiting myeloid cells from peripheral blood, Gw2580 (160 mg/kg) causes a more than two-fold decrease in total CD45+ CD11b+ myeloid cells, CD11b+ F4/80+ TAMs, and CD11b+ Gr-1+ MDSCs in implanted 3LL lung tumors. Treatment with GW2580 (80 mg/kg) can reduce tumor vascular density (CD31 staining) and the expression of Vegf-a (by 35%) and Mmp9 (by 70%). Combination therapy involving GW2580 and an anti-VEGFR-2 antibody reduces tumor growth in a synergistic manner. While DC101 by itself inhibits tumor growth by 35%, when combined with GW2580, there appears to be a synergistic reduction in tumor growth of about 70%.[2]
Enzyme Assay
After 90 minutes at room temperature, 10 μM enzyme, 100 μM ATP, and 5 mM MgCl2 are incubated in 50 mM Tris HCL to activate the enzyme through autophosphorylation. Round-bottom polystyrene 96-well plates on a Biomek 2000 are used to conduct 45 μL enzyme reactions. In each well, 30 mL of a 1.5-substrate reaction mix containing 50 mM Mops (3-[N-Morpholino]propanesulfonic acid), pH 7.5, 15 mM MgCl2, 6 M peptide substrate, and biotin-EAIYAPFAKKK-NH2 is added, either alone or in 1 mL of DMSO. 0.5 μCi (1 Ci = 37 GBq) [33P-γ] ATP, 75 mM NaCl, 10 μM ATP, and 7.5 mM DTT are needed for each assay. The final enzyme concentration is 20 nM, and the reaction is started by adding 15 μL of diluted enzyme solution. Background is determined by adding EDTA to the control wells. A 96-well phosphocellulose filter plate is prewet with 100 μL of 0.5% phosphoric acid, and 75 μL of the reaction is transferred to it after it has been allowed to proceed for 40 minutes and stopped by adding an equal volume of the acid. Following three rounds of washing with the phosphoric acid solution and filtering on a Millipore filter-plate vacuum manifold, 40 μL of scintillation solution is added. In a Packard Topcount NXT scintillation counter, the plates are sealed and tallied.
Cell Assay
The cells are spun down and diluted media-infused with 2× 106 cells/ml for 24 hours prior to the commencement of the cell growth assay. M-NSF60 cell depleted medium is devoid of MCSF. The following day, GW2580 at 10 mM in DMSO is serially diluted to produce a 10-point concentration curve, starting at 20 μM and 0.2% DMSO in medium containing 10% serum. After being resuspended in medium, the M-NFS-60 cells are added to 0.5× 106 cells/mL along with 10% serum and 20 ng/mL mouse MCSF. Each well is filled with 50 μL of inhibitor-containing cells, and then, after three days, 10 μL of WST-1 reagent is added to each well. Growth is determined by measuring the difference between wells with full medium and wells with depleted medium after a 4-hour incubation period. The absorbance is measured at 440 nm.
Animal Protocol
Mouse myeloid carcinoma xenografts M-NFS-60
80 mg/kg
Orally twice a day
References

[1]. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83.

[2]. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010 Feb 18;115(7):1461-71

[3]. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther. 2008 Jul;326(1):41-50.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C20H22N4O3
Molecular Weight
366.41
Exact Mass
366.17
Elemental Analysis
C, 65.56; H, 6.05; N, 15.29; O, 13.10
CAS #
870483-87-7
Appearance
white solid powder
SMILES
COC1=CC=C(C=C1)COC2=C(C=C(C=C2)CC3=CN=C(N=C3N)N)OC
InChi Key
MYQAUKPBNJWPIE-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)
Chemical Name
5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine
Synonyms
GW 2580; SC-203877; SC 203877; GW 2580; GW-2580; SC203877
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~48 mg/mL (~131.0 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
5% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5 mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.7292 mL 13.6459 mL 27.2918 mL
5 mM 0.5458 mL 2.7292 mL 5.4584 mL
10 mM 0.2729 mL 1.3646 mL 2.7292 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • GW2580

    Angiogenesis and growth kinetics of tumors treated with GW2580. Blood. 2010 Feb 18; 115(7): 1461–1471.


  • GW2580

    TIMs mediate MMP-9 induction by anti–VEGFR-2 therapy. Blood. 2010 Feb 18; 115(7): 1461–1471.

  • GW2580

    Targeting MDSC infiltration and tumor angiogenesis in orthotopic RM-1 prostate tumors. Blood. 2010 Feb 18;115(7):1461-71.

Contact Us